Clinical Trials Browser

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01038778 2026-03-18

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Phase 1/2 Active not recruiting

47 enrolled 15 charts

Genitourinary

Carcinoma, Renal Cell

NCT01064648 2026-03-18

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1/2 Active not recruiting

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01089101 2026-03-18

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

220 enrolled

CNS

Astrocytoma, Neurofibromatosis 1

NCT01386385 2026-03-18

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

53 enrolled 21 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT01468896 2026-03-18

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

23 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02535312 2026-03-18

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1/2 Active not recruiting

30 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03604978 2026-03-18

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Phase 1/2 Active not recruiting

38 enrolled

CNS

Meningioma

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04140500 2026-03-18

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

170 enrolled

DermatologicGastrointestinalThoracic

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04181788 2026-03-18

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Phase 1/2 Active not recruiting

155 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04317105 2026-03-18

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

54 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04557956 2026-03-18

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Phase 1/2 Active not recruiting

16 enrolled

Dermatologic

Melanoma

NCT04699188 2026-03-18

KontRASt-01

Phase 1/2 Active not recruiting

344 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05286801 2026-03-18

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase 1/2 Active not recruiting

86 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT06590857 2026-03-18

TRACY-1

Phase 1/2 Active not recruiting

16 enrolled

Breast

Breast Neoplasms

NCT04802174 2026-03-17

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Phase 1/2 Active not recruiting

37 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

24 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

75 enrolled

Breast

Breast Neoplasms

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05194995 2026-03-16

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Phase 1/2 Active not recruiting

48 enrolled

Gastrointestinal

Appendiceal Neoplasms

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

40 enrolled

Breast

HER2-positive Metastatic Breast Cancer

NCT05562830 2026-03-16

MK-3475-04A

Phase 1/2 Active not recruiting

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06116136 2026-03-16

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Phase 1/2 Active not recruiting

48 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06561425 2026-03-16

Atalanta-1

Phase 1/2 Active not recruiting

130 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03786081 2026-03-13

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Active not recruiting

214 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05009329 2026-03-13

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Phase 1/2 Active not recruiting

315 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

Phase 1/2 Active not recruiting

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02908906 2026-03-12

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

413 enrolled

Tumor-Agnostic

Neoplasms

NCT03145181 2026-03-12

MajesTEC-1

Phase 1/2 Active not recruiting

302 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT05099172 2026-03-12

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 1/2 Active not recruiting

370 enrolled 1 FDA

Thoracic

Advanced Non-small Cell Lung Cancer

NCT06057922 2026-03-12

A Study YL201 in Patients With Selected Advanced Solid Tumors

Phase 1/2 Active not recruiting

990 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Phase 1/2 Active not recruiting

43 enrolled 30 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

40 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06083857 2026-03-11